Mitochondrial dysfunction and Parkinson disease: a Parkin–AMPK alliance in neuroprotection

Annals of the New York Academy of Sciences

Volumn 1350, Issue 1, 2015, Pages 37-47

  Hang, Liting ^a,b   Thundyil, John ^a   Lim, Kah Leong ^a,b,c,d  

^a NATIONAL NEUROSCIENCE INSTITUTE   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c DUKE NUS MEDICAL SCHOOL   (Singapore)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

dopamine; LRRK2; mitophagy; neurodegeneration; PGC 1 ; PINK1

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; PARKIN;

ARTICLE; HOMEOSTASIS; MITOCHONDRION; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; NEUROPROTECTION; PARKINSON DISEASE;

EID: 84933557447     PISSN: 00778923     EISSN: 17496632     Source Type: Journal    
DOI: 10.1111/nyas.12820     Document Type: Article

References (73)

1. Dorsey, E.R. et al. 2007. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 68: 384–386.
2. Braak, H. et al. 2003. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging. 24: 197–211.
3. Jankovic, J. 2008. Parkinson's disease: clinical features and diagnosis. J. Neurol. Neurosurg. Psychiatry 79: 368–376.
4. Langston, J.W. et al. 1983. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219: 979–980.
5. Schapira, A.H. et al. 1989. Mitochondrial complex I deficiency in Parkinson's disease. Lancet 1: 1269.
6. Shults, C.W. et al. 1997. Coenzyme Q10 levels correlate with the activities of complexes I and II/III in mitochondria from parkinsonian and nonparkinsonian subjects. Ann. Neurol. 42: 261–264.
7. Parker, W.D., Jr., S.J. Boyson & J.K. Parks. 1989. Abnormalities of the electron transport chain in idiopathic Parkinson's disease. Ann. Neurol. 26: 719–723.
8. Dauer, W. & S. Przedborski. 2003. Parkinson's disease: mechanisms and models. Neuron 39: 889–909.
9. Betarbet, R. et al. 2000. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat. Neurosci. 3: 1301–1306.
10. Sterky, F.H. et al. 2011. Impaired mitochondrial transport and Parkin-independent degeneration of respiratory chain-deficient dopamine neurons in vivo. Proc. Natl. Acad. Sci. U.S.A. 108: 12937–12942.
11. Tanner, C.M. et al. 2011. Rotenone, paraquat, and Parkinson's disease. Environ. Health Perspect. 119: 866–872.
12. Caparros-Lefebvre, D. & A. Elbaz. 1999. Possible relation of atypical parkinsonism in the French West Indies with consumption of tropical plants: a case-control study. Caribbean Parkinsonism Study Group. Lancet 354: 281–286.
13. Chen, H. & D.C. Chan. 2009. Mitochondrial dynamics–fusion, fission, movement, and mitophagy–in neurodegenerative diseases. Hum. Mol. Genet. 18: R169–R176.
14. Greene, J.C. et al. 2003. Mitochondrial pathology and apoptotic muscle degeneration in Drosophila parkin mutants. Proc. Natl. Acad. Sci. U.S.A. 100: 4078–4083.
15. Guo, M. 2010. What have we learned from Drosophila models of Parkinson's disease? Prog. Brain Res. 184: 3–16.
16. Youle, R.J. & D.P. Narendra. 2011. Mechanisms of mitophagy. Nat. Rev. Mol. Cell Biol. 12: 9–14.
17. Okatsu, K. et al. 2012. PINK1 autophosphorylation upon membrane potential dissipation is essential for Parkin re-cruitment to damaged mitochondria. Nat. Commun. 3: 1016.
18. Kane, L.A. et al. 2014. PINK1 phosphorylates ubiquitin to activate Parkin E3 ubiquitin ligase activity. J. Cell Biol. 205: 143–153.
19. Koyano, F. et al. 2014. Ubiquitin is phosphorylated by PINK1 to activate parkin. Nature 510: 162–166.
20. Matsuda, N. et al. 2010. PINK1 stabilized by mitochondrial depolarization recruits Parkin to damaged mitochondria and activates latent Parkin for mitophagy. J. Cell Biol. 189: 211–221.
21. Kondapalli, C. et al. 2012. PINK1 is activated by mitochondrial membrane potential depolarization and stimulates Parkin E3 ligase activity by phosphorylating Serine 65. Open Biol. 2: 120080.
22. Okatsu, K. et al. 2015. Phosphorylated ubiquitin chain is the genuine Parkin receptor. J. Cell Biol. 209: 111–128.
23. Ordureau, A. et al. 2014. Quantitative proteomics reveal a feedforward mechanism for mitochondrial PARKIN translocation and ubiquitin chain synthesis. Mol. Cell 56: 360–375.
24. Shiba-Fukushima, K. et al. 2014. Phosphorylation of mitochondrial polyubiquitin by PINK1 promotes Parkin mitochondrial tethering. PLoS Genet. 10: e1004861.
25. Poole, A.C. et al. 2010. The mitochondrial fusion-promoting factor mitofusin is a substrate of the PINK1/parkin pathway. PLoS One 5: e10054.
26. Ziviani, E., R.N. Tao & A.J. Whitworth. 2010. Drosophila parkin requires PINK1 for mitochondrial translocation and ubiquitinates mitofusin. Proc. Natl. Acad. Sci. U.S.A. 107: 5018–5023.
27. Wang, X. et al. 2011. PINK1 and Parkin target Miro for phosphorylation and degradation to arrest mitochondrial motility. Cell 147: 893–906.
28. Ashrafi, G. et al. 2014. Mitophagy of damaged mitochondria occurs locally in distal neuronal axons and requires PINK1 and Parkin. J. Cell Biol. 206: 655–670.
29. Shin, J.H. et al. 2011. PARIS (ZNF746) repression of PGC-1alpha contributes to neurodegeneration in Parkinson's disease. Cell 144: 689–702.
30. Scarpulla, R.C. 2008. Nuclear control of respiratory chain expression by nuclear respiratory factors and PGC-1-related coactivator. Ann. N.Y. Acad. Sci. 1147: 321–334.
31. Perez, F.A. & R.D. Palmiter. 2005. Parkin-deficient mice are not a robust model of parkinsonism. Proc. Natl. Acad. Sci. U.S.A. 102: 2174–2179.
32. Moore, D.J. 2006. Parkin: a multifaceted ubiquitin ligase. Biochem. Soc. Trans. 34: 749–753.
33. Hardie, D.G., F.A. Ross & S.A. Hawley. 2012. AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nat. Rev. Mol. Cell Biol. 13: 251–262.
34. Lim, C.T., B. Kola & M. Korbonits. 2010. AMPK as a mediator of hormonal signalling. J. Mol. Endocrinol. 44: 87–97.
35. Zhou, G. et al. 2001. Role of AMP-activated protein kinase in mechanism of metformin action. J. Clin. Invest. 108: 1167–1174.
36. Baur, J.A. et al. 2006. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 444: 337–342.
37. Collins, Q.F. et al. 2007. Epigallocatechin-3-gallate (EGCG), a green tea polyphenol, suppresses hepatic gluconeogenesis through 5′-AMP-activated protein kinase. J. Biol. Chem. 282: 30143–30149.
38. Zong, H. et al. 2002. AMP kinase is required for mitochondrial biogenesis in skeletal muscle in response to chronic energy deprivation. Proc. Natl. Acad. Sci. U.S.A. 99: 15983–15987.
39. Jager, S. et al. 2007. AMP-activated protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1alpha. Proc. Natl. Acad. Sci. U.S.A. 104: 12017–12022.
40. Canto, C. et al. 2010. Interdependence of AMPK and SIRT1 for metabolic adaptation to fasting and exercise in skeletal muscle. Cell Metab. 11: 213–219.
41. Kim, J. et al. 2011. AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. Nat. Cell Biol. 13: 132–141.
42. Egan, D.F. et al. 2011. Phosphorylation of ULK1 (hATG1) by AMP-activated protein kinase connects energy sensing to mitophagy. Science 331: 456–461.
43. Kwon, K.Y., B. Viollet & O.J. Yoo. 2011. CCCP induces autophagy in an AMPK-independent manner. Biochem. Biophys. Res. Commun. 416: 343–348.
44. Feany, M.B. & L.J. Pallanck. 2003. Parkin: a multipurpose neuroprotective agent? Neuron 38: 13–16.
45. Winklhofer, K.F. 2007. The parkin protein as a therapeutic target in Parkinson's disease. Expert Opin. Ther. Targets 11: 1543–1552.
46. Wang, C. et al. 2007. Drosophila overexpressing parkin R275W mutant exhibits dopaminergic neuron degeneration and mitochondrial abnormalities. J. Neurosci. 27: 8563–8570.
47. Lee, J.Y. et al. 2010. Disease-causing mutations in Parkin impair mitochondrial ubiquitination, aggregation, and HDAC6-dependent mitophagy. J. Cell Biol. 189: 671–679.
48. Lim, K.L. et al. 2012. Mitochondrial dynamics and Parkinson's disease: focus on parkin. Antioxid. Redox Signal. 16: 935–949.
49. Pertsch, M. et al. 1988. A histochemical study of the regional distribution in the rat brain of enzymatic activity hydrolyzing glucose-and 2-deoxyglucose-6-phosphate. Histochemistry 88: 257–262.
50. McCullough, L.D. et al. 2005. Pharmacological inhibition of AMP-activated protein kinase provides neuroprotection in stroke. J. Biol. Chem. 280: 20493–20502.
51. Ju, T.C. et al. 2011. Nuclear translocation of AMPK-alpha1 potentiates striatal neurodegeneration in Huntington's disease. J. Cell Biol. 194: 209–227.
52. Ma, T.C. et al. 2007. Metformin therapy in a transgenic mouse model of Huntington's disease. Neurosci. Lett. 411: 98–103.
53. Martin-Montalvo, A. et al. 2013. Metformin improves healthspan and lifespan in mice. Nat. Commun. 4: 2192.
54. Culmsee, C. et al. 2001. AMP-activated protein kinase is highly expressed in neurons in the developing rat brain and promotes neuronal survival following glucose deprivation. J. Mol. Neurosci. 17: 45–58.
55. Vingtdeux, V. et al. 2010. AMP-activated protein kinase signaling activation by resveratrol modulates amyloid-beta peptide metabolism. J. Biol. Chem. 285: 9100–9113.
56. Tschape, J.A. et al. 2002. The neurodegeneration mutant lochrig interferes with cholesterol homeostasis and Appl processing. EMBO J. 21: 6367–6376.
57. Spasic, M.R., P. Callaerts & K.K. Norga. 2008. Drosophila alicorn is a neuronal maintenance factor protecting against activity-induced retinal degeneration. J. Neurosci. 28: 6419–6429.
58. Choi, J.S., C. Park & J.W. Jeong. 2010. AMP-activated protein kinase is activated in Parkinson's disease models mediated by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Biochem. Biophys. Res. Commun. 391: 147–151.
59. Wu, Y. et al. 2011. Resveratrol-activated AMPK/SIRT1/autophagy in cellular models of Parkinson's disease. Neurosignals 19: 163–174.
60. Kim, T.W. et al. 2013. (ADP-ribose) polymerase 1 and AMP-activated protein kinase mediate progressive dopaminergic neuronal degeneration in a mouse model of Parkinson's disease. Cell Death Dis. 4: e919.
61. Xu, Y. et al. 2014. Activation of AMPK and inactivation of Akt result in suppression of mTOR-mediated S6K1 and 4E-BP1 pathways leading to neuronal cell death in in vitro models of Parkinson's disease. Cell Signal. 26: 1680–1689.
62. Wahlqvist, M.L. et al. 2012. Metformin-inclusive sulfonylurea therapy reduces the risk of Parkinson's disease occurring with Type 2 diabetes in a Taiwanese population cohort. Parkinsonism Relat. Disord. 18: 753–758.
63. Ng, C.H. et al. 2012. AMP kinase activation mitigates dopaminergic dysfunction and mitochondrial abnormalities in Drosophila models of Parkinson's disease. J. Neurosci. 32: 14311–14317.
64. Hwang, J.T., D.Y. Kwon & S.H. Yoon. 2009. AMP-activated protein kinase: a potential target for the diseases prevention by natural occurring polyphenols. N. Biotechnol. 26: 17–22.
65. Spasic, M.R., P. Callaerts & K.K. Norga. 2009. AMP-activated protein kinase (AMPK) molecular crossroad for metabolic control and survival of neurons. Neuroscientist 15: 309–316.
66. Shieh, D.E., L.T. Liu & C.C. Lin. 2000. Antioxidant and free radical scavenging effects of baicalein, baicalin and wogonin. Anticancer Res. 20: 2861–2865.
67. Ng, C.H. et al. 2009. Parkin protects against LRRK2 G2019S mutant-induced dopaminergic neurodegeneration in Drosophila. J. Neurosci. 29: 11257–11262.
68. Martin, I., V.L. Dawson & T.M. Dawson. 2011. Recent advances in the genetics of Parkinson's disease. Annu. Rev. Genomics Hum. Genet. 12: 301–325.
69. Ferretta, A. et al. 2014. Effect of resveratrol on mitochondrial function: implications in Parkin-associated familiar Parkinson's disease. Biochim. Biophys. Acta. 1842: 902–915.
70. VanRompuy, A.S. et al. 2014. Long-term overexpression of human wild-type and T240R mutant Parkin in rat substantia nigra induces progressive dopaminergic neurodegeneration. J. Neuropathol. Exp. Neurol. 73: 159–174.
71. Carroll, R.G., E. Hollville & S.J. Martin. 2014. Parkin sensitizes toward apoptosis induced by mitochondrial depolarization through promoting degradation of Mcl-1. Cell Rep. 9: 1538–1553.
72. Lim, K.L. & C.W. Zhang. 2013. Molecular events underlying Parkinson's disease—an interwoven tapestry. Front Neurol. 4: 33.
73. Rana, A., M. Rera & D.W. Walker. 2013. Parkin overexpression during aging reduces proteotoxicity, alters mitochondrial dynamics, and extends lifespan. Proc. Natl. Acad. Sci. U.S.A. 110: 8638–8643.